Key AstraZeneca PLC Financials
| Company Type | Public -(London: AZN) Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Sales (mil.) | $33,591.0 |
| 2010 Employees | 61,000 |
AstraZeneca PLC Stock Quote (NYSE: AZN)(London: AZN)
| Latest 02/15/12 15:38:47 EST | Change ($) | Change (%) | High | Low |
|---|---|---|---|---|
| $45.22 |  -0.420 | -0.920 | $45.70 | $45.16 |
Quotes delayed 15 minutes for NASDAQ, 20 minues for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions. |
AstraZeneca PLC Income Statement
| Dec 11 | Dec 10 | Dec 09 | |
| Revenue | 33,591.0 | 33,269.0 | 32,804.0 |
| Cost of Goods Sold | 6,026.0 | 6,389.0 | 5,775.0 |
| Gross Profit | 27,565.0 | 26,880.0 | 27,029.0 |
| Gross Profit Margin | 82.1% | 80.8% | 82.4% |
| SG&A Expense | 11,507.0 | 10,780.0 | 11,630.0 |
| Depreciation & Amortization | 2,550.0 | 2,741.0 | 2,087.0 |
| Operating Income | 12,795.0 | 11,494.0 | 11,543.0 |
| Operating Margin | 38.1% | 34.5% | 35.2% |
| Nonoperating Income | 0.0 | 0.0 | 0.0 |
| Nonoperating Expenses | (428.0) | (517.0) | (736.0) |
| Income Before Taxes | 12,367.0 | 10,977.0 | 10,807.0 |
| Income Taxes | 2,351.0 | 2,896.0 | 3,263.0 |
| Net Income After Taxes | 10,016.0 | 8,081.0 | 7,544.0 |
| Continuing Operations | 9,983.0 | 8,053.0 | 7,521.0 |
| Discontinued Operations | -- | -- | -- |
| Total Operations | 9,983.0 | 8,053.0 | 7,521.0 |
| Total Net Income | 9,983.0 | 8,053.0 | 7,521.0 |
| Net Profit Margin | 29.7% | 24.2% | 22.9% |
| Diluted EPS from Total Net Income | 7.30 | 5.57 | 5.19 |
| Dividends per Share | 2.70 | 2.41 | 2.09 |
All amounts in millions of US Dollars except per share amounts.
AstraZeneca PLC Balance Sheet
| Assets | Dec 11 | Dec 10 | Dec 09 |
| Current Assets | |||
| Cash | 7,571.0 | 11,068.0 | 9,918.0 |
| Net Receivables | 9,810.0 | 10,890.0 | 10,584.0 |
| Inventories | 1,852.0 | 1,682.0 | 1,750.0 |
| Other Current Assets | 4,273.0 | 1,491.0 | 1,508.0 |
| Total Current Assets | 23,506.0 | 25,131.0 | 23,760.0 |
| Net Fixed Assets | 6,425.0 | 6,957.0 | 7,307.0 |
| Other Noncurrent Assets | 22,899.0 | 24,039.0 | 23,853.0 |
| Total Assets | 52,830.0 | 56,127.0 | 54,920.0 |
| Liabilities | Dec 11 | Dec 10 | Dec 09 |
| Current Liabilities | |||
| Accounts Payable | 8,975.0 | 8,661.0 | 8,687.0 |
| Short-Term Debt | 1,990.0 | 125.0 | 1,926.0 |
| Other Current Liabilities | 4,787.0 | 8,001.0 | 7,027.0 |
| Total Current Liabilities | 15,752.0 | 16,787.0 | 17,640.0 |
| Long-Term Debt | 7,338.0 | 9,470.0 | 244.0 |
| Other Noncurrent Liabilities | 6,494.0 | 6,657.0 | 16,376.0 |
| Total Liabilities | 29,584.0 | 32,914.0 | 34,260.0 |
| Shareholder's Equity | |||
| Preferred Stock Equity | -- | -- | -- |
| Common Stock Equity | 23,246.0 | 23,213.0 | 20,660.0 |
| Total Equity | 23,246.0 | 23,213.0 | 20,660.0 |
| Shares Outstanding (thou.) | 1,320,493.4 | 1,409,023.5 | 1,450,958.6 |
All amounts in millions of US Dollars except per share amounts.
AstraZeneca PLC Cash Flow Statement
| Dec 11 | Dec 10 | Dec 09 | |
| Net Operating Cash Flow | 7,821 | 10,680 | 11,739 |
| Net Investing Cash Flow | (2,022.0) | (2,340.0) | (2,476.0) |
| Net Financing Cash Flow | (9,321.0) | (7,220.0) | (3,629.0) |
| Net Change in Cash | (3,522.0) | 1,120.0 | 5,634.0 |
| Depreciation & Amortization | 2,550.0 | 2,741.0 | 2,087.0 |
| Capital Expenditures | (1,297.0) | (2,181.0) | (2,957.0) |
| Cash Dividends Paid | (3,764.0) | (3,361.0) | (2,977.0) |
All amounts in millions of US Dollars except per share amounts.